Jefferies Financial Group provided a buy rating and price target for Hemab Therapeutics.
2 reports, 2 independent
Updated Oct 8
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Jefferies Financial Group provided a buy rating and price target for Hemab Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Analyst reports are affecting stock price targets for various companies, with company data being summarized on financial blogs.Also in this story
- Jefferies Financial Group restated its buy rating on Paylocity, while Truist Financial cut its target price.
- Financial firms including Bank of America, Morgan Stanley, and Truist Financial adjusted price targets and ratings for Somnigroup International Inc.
- Truist Financial issued a buy rating for a company, with MarketBeat providing average rating data.
- Analyst firms provided research reports and aggregated market data for Sensata Technologies.
The entities involved
-
Jefferies Financial Group
American financial services company
-
MarketBeat
American personal finance blog
Related events
- GE Vernova received a 'buy' rating and target price raise from Jefferies, alongside required SEC filings on May 27, 2026.
- Analyst coverage for Septerna, including a new outperform rating from Raymond James Financial and coverage assumption by Truist Financial, reported via MarketBeat.
- Jefferies Financial Group initiated coverage of Suja Life, Inc., providing a buy rating and price objective as of July 18, 2026.
- MarketBeat provided a consensus rating and target price for Carriage Services, Inc., following a price target set by Raymond James Financial.
- Jefferies Financial Group issued a buy rating and price target for VOLEX PLC.